Biopharma firms are in-licensing candidates later according to an industry expert, who says the trend is impacting the CDMO sector. In-licensing – the practice of paying for rights to develop and commercialize a product discovered by another company – is a widely used strategy in the biopharmaceutical industry. According to a recent report in Nature the top 10 drug licensing deals in the first three quarters of 2019 were worth $34 billion (€31 billion), an increase of 10% from the…